Assessment of uric acid-lowering activity, safety and stress tolerance of Lactiplantibacillus plantarum MC14 based on whole gene sequencing and phenotyping experiments

Abstract

With lifestyle changes, hyperuricemia has become a global epidemic. Recent studies have indicated that some probiotic strains may help control serum uric acid. This study aimed to screen probiotic strains with uric acid-lowering potential and subsequently analyze the safety and stress tolerance of the strain in food applications, utilizing phenotyping experiments and genome sequencing. Initially, we isolated a strain of Lactiplantibacillus plantarum MC14 with the best in vitro uric acid-lowering activity. The inosine and guanosine degradation rates of MC14 were 5.00 and 4.11 mg/L·min, respectively, and the XOD inhibition rate was 81.56% ± 3.87%. Gene analysis revealed that the MC14 strain encodes three nucleoside hydrolases and six nucleoside and nucleobase transporter proteins. Subsequently, safety assessments of the MC14 strain in food applications revealed no nitroreductase, amino decarboxylase, or tryptophanase activities, absence of hemolysis, and no antibiotic resistance gene transfer risk. Finally, stress tolerance tests on MC14 indicated robust tolerance to gastrointestinal fluids and bile salts, with survival rates exceeding 98% after 3 h in artificial gastric fluids and approximately 100.49% ± 0.15% after 8 h in artificial intestinal fluids. Additionally, MC14 demonstrated effective antibacterial properties and antioxidant capacity, and its genome was annotated with numerous stress tolerance-related genes, including 18 acid-base stress, 4 bile salt tolerance, 11 heat stress, 3 cold stress, 6 osmotic stress, and 28 oxidative stress. Our findings highlighted MC14 as a promising candidate for probiotic and food applications.